Using Blood Proteins to Improve the Understanding and Treatment of Heart Disease

Using Blood Proteins to Improve the Understanding and Treatment of Heart Disease

Research question and funding constraint

This project combines chemically different protein measurements with population epidemiology to distinguish robust cardiovascular signals from assay artefacts. It offers a strong analytical training bridge between Mayr’s proteomics and Tzoulaki’s causal research. The project call lists a three-year award beginning in 2027 and a 15 November 2026 deadline, but covers only Home tuition. Whether applications are still being accepted is unconfirmed. An overseas applicant must secure the fee difference separately. The next useful action is to obtain that fee quote and funding route before treating the award as financially viable.

Official BHF blood-protein PhD call

Research Problem and Doctoral Work

The project tackles two linked uncertainties: whether a measured blood-protein signal is analytically reliable, and what a reliable signal tells us about cardiovascular disease. Affinity platforms can measure thousands of targets efficiently, but their signals may reflect epitopes, cross-reactivity, dynamic-range limits or genetic binding effects as well as protein abundance. Mass spectrometry offers a chemically different measurement route. Neither approach is automatically error-free, so a useful thesis would investigate agreement and failure modes rather than simply choose one platform as the truth.

The advertised work integrates MS, affinity proteomics, genetics and clinical outcomes from well-characterised cohorts. Its statistical and causal analyses aim to identify robust proteins and prioritise biomarkers or therapeutic targets. Exact cohort names, participant numbers and the proportion of new laboratory acquisition versus existing data are not specified.

UK Biobank is directly relevant to the supervisors' papers, but it is not confirmed as the sole or guaranteed doctoral dataset.

The cited UK Biobank information distinguishes available proteomic coverage from planned larger coverage. A September 2026 access notice described preparations to reopen access after platform strengthening; that historical notice does not establish a new student's current access.

A possible research sequence, offered as analysis rather than an assigned work package, starts with assay quality control and batch diagnostics; examines platform concordance by concentration range and genetic variant; investigates disease associations with appropriate confounder control; then tests causal hypotheses and out-of-sample prediction separately. Sensitivity analyses should address missingness, sample handling and whether instruments alter abundance or binding.

Colocalisation can improve interpretation of overlapping genetic associations, but cannot by itself prove that modifying a protein will improve an outcome.

Prediction must be judged on calibration and incremental utility as well as discrimination.

The doctorate could produce an analytical validation framework, a reproducible comparative dataset or a carefully qualified shortlist for further biology. Those are realistic scientific contributions even if no marker reaches clinical adoption within three years. The distinction between analytical validity, disease association, causal plausibility and clinical usefulness is central to project quality.

Field and career directions

UK life-sciences policy supports health data, prevention and translation, and its jobs plan recognises demand for research and digital skills. This supports plausible career directions in molecular epidemiology, biomedical data analysis, proteomics, biomarker development and pharmaceutical target discovery. It does not establish a guaranteed industry position or justify importing sector-average salaries into a graduate forecast. Clinical implementation additionally requires external validation, cost-effectiveness and regulatory work beyond this PhD's stated remit.

Official BHF blood-protein PhD call Blood pressure, plasma proteins and cardiovascular diseases Precision medicine requires precision proteomics UK Life Sciences Sector Plan, updated July 2026 UK Life Sciences Jobs Plan UK Biobank biomarker and proteomic data coverage UK Biobank current data-access status

School, Programme and Research Environment

Imperial College London is the prospective degree-awarding institution; the personal registration department remains to be confirmed. Imperial provides an unusually relevant combination of cardiovascular experimental biology and population epidemiology. The studentship is jointly supported by its British Heart Foundation Centre of Research Excellence and School of Public Health. The centre spans Hammersmith and White City, while the public-health school is at White City. The research setting therefore connects molecular measurements with cohort analysis rather than treating proteomics as an isolated laboratory activity.

QS's primary 2027 rankings summary places Imperial equal second globally with Stanford. This is an institutional reputation signal, not a rating of this particular project or a measure of doctoral supervision. NHLI's cardiac and vascular research and the School of Public Health's epidemiological programmes are more directly relevant. The project's established doctoral programme advertises seminars, teaching, mentoring and workshops. Current ECRI resources additionally support communication, integrity and professional progression.

A potential advantage is exposure to both laboratory quality assurance and the reasoning needed to evaluate disease associations. Cross-group work also brings practical coordination questions: which department hosts registration, where the student spends most working days, and whether analytic and experimental priorities are agreed jointly. NHLI's general PhD application route uses supervisor agreement followed by a formal Imperial application; the initial competitive studentship application has its own email route. Those are successive stages, not interchangeable submissions.

Institutional resources are credible, but the public pages do not establish instrument booking allocations, cohort access rights, student completion outcomes or individual meeting arrangements. Broad rankings should support confidence in the environment while leaving these operational questions open.

Official BHF blood-protein PhD call QS World University Rankings 2027 primary summary National Heart and Lung Institute research Imperial School of Public Health NHLI doctoral application route Current doctoral professional development support

Supervisor, Publications and Laboratory

Manuel Mayr is Imperial's BHF Professor of Cardiovascular Proteomics and co-director of the BHF research centre. His official profile records the move of his BHF chair to Imperial in 2023, which resolves older King’s College affiliations still visible elsewhere. Ioanna Tzoulaki is Professor of Chronic Disease Epidemiology and leads the centre's population-health theme. Her programme examines molecular and genetic determinants of chronic disease and risk stratification. The current project explicitly names both as supervisors, providing a substantive experimental–epidemiological pairing.

Three recent publications can be identified precisely from primary records. Lundby, Van Eyk, Mayr, White, Kirk, Achter, Fert-Bober, Wierer, Mertins, Lam, Humphrey, Lau, Gramolini, Ge and Gundry (2026), Consensus statement on mass spectrometry-based proteomic analysis of cardiac tissue, Nature Cardiovascular Research 5:526–540, DOI 10.1038/s44161-026-00824-4, sets out reproducibility and reporting issues surrounding cardiac tissue. It strengthens the case for careful preanalytics and transparent analytical workflows; it is a consensus statement on tissue, not proof of performance for this project's plasma assay.

Meena and colleagues, including Mayr and Tzoulaki (2026 issue; online 2025), Blood pressure, plasma proteins, and cardiovascular diseases: a network Mendelian randomization and observational study, European Heart Journal 47:331–342, DOI 10.1093/eurheartj/ehaf725, combines observational and genetic evidence to investigate candidate protein pathways between blood pressure and cardiovascular disease. The relevance is the integration of associations, genetic instruments and colocalisation.

The analysis examined 2,007 proteins with cis instruments from a 2,923-protein panel, with 242 blood-pressure and 48 cardiovascular-disease signals and four prioritised proteins (ACOX1, FGF5, FURIN and MST1). These are prioritisation results, not proven treatments.

Its candidates still need biological validation; MR depends on assumptions about instruments and competing pathways.

Singh, Tzoulaki and Mayr (2025), Precision medicine requires precision proteomics: discordance between proteomic and clinical assays in UK Biobank, Cardiovascular Research 121:2293–2295, DOI 10.1093/cvr/cvaf167, identifies discrepancies involving ApoB and lipoprotein(a). A high correlation across an entire cohort can hide poor agreement in clinically important ranges. Repeating an affinity assay in another cohort is not the same as orthogonal analytical validation. This research letter gives the proposed doctorate a concrete, current scientific motivation.

The 2026 consensus contributes only publisher-metadata and abstract-level context; its detailed recommendations are outside the evidence discussed here. It is supporting guidance, not one of the three original empirical studies. The Meena analysis described here is limited to its main methods, selected results and stated limitations. European-ancestry data, possible protein-altering variants and residual sample overlap limit generalisation and causal interpretation.

Meena and Huang are joint first authors and Tzoulaki is corresponding author; Mayr is a coauthor, with individual analytic tasks unconfirmed. Singh's research letter contains an original UK Biobank reanalysis: its figure methods and author contributions identify Singh as analyst/drafter, Mayr as co-conceptor/reviser and Tzoulaki as resource provider/reviewer. Supplementary materials and raw data are outside the evidence described here.

Theofilatos, Stojkovic and colleagues' 2023 original plaque-proteomics study (DOI 10.1161/CIRCRESAHA.123.322590) supplies a third empirical precedent. Sequential extraction, discovery mass spectrometry and targeted validation used 219 specimens from 120 discovery patients and a separate 200-patient validation cohort.

A four-protein plaque prognostic model changed from 75.0% cross-validated AUC in discovery to 67.5% in external validation, not a result for this plasma project.

Integrating molecular measurements with tissue and outcome information illustrates a design-test-validation chain. Advanced carotid lesions, all-white cohorts, limited detection of low-abundance proteins and only two spatial-RNA samples restrict extrapolation; tissue results cannot be assigned to this plasma project. The study's main methods, selected results and reported limitations support this comparison.

Theofilatos and Stojkovic share first authorship; Wojta and Mayr share senior authorship, without a claim that Mayr performed every assay. Original plaque study.

Mayr's group resources describe integrated proteomic and other molecular profiling. Imperial also has White City mass-spectrometry infrastructure with instrument training and booking charges. The exact project promises MS work in Mayr's laboratory, but does not publish the intended instrument, throughput or reserved experimental capacity.

Joint supervision is a strength when there is an agreed bridge between measurement quality and epidemiological interpretation. Meeting frequency, division of responsibility and support for students crossing between wet-lab and statistical work should be established at interview. Public sources do not substantiate project-specific alumni or placement rates.

Manuel Mayr Imperial staff profile Ioanna Tzoulaki Imperial staff profile Mayr cardiovascular proteomics group research and publications Consensus statement on MS-based cardiac-tissue proteomics Blood pressure, plasma proteins and cardiovascular diseases Precision medicine requires precision proteomics White City MS infrastructure and training

Funding, Application and Living Cost

Three-year award and overseas fees

The exact official call confirms three years of funding starting in 2027, with a stipend beginning at £24,323 annually. It also specifies £5,000 per year in consumables and £1,000 in travel funding across all three years. Research and travel allowances are project budgets, not additional personal living income. Future stipend increments or an extension beyond three years are not explicitly guaranteed.

The most important financing restriction is explicit: the award pays Home fees, while an overseas student must cover the fee difference from another source. International participation is therefore possible, but this is not a complete overseas-fee scholarship. A Chinese applicant's fee status requires the university's formal assessment; Chinese nationality alone does not determine every residency case. A typical applicant assessed as overseas needs a confirmed supplementary funding arrangement before acceptance. No general Imperial or CSC award is assumed to be available, stackable or linked to this project.

Imperial's 2026–27 doctoral fee policy routes NHLI and Public Health through the Faculty of Medicine and describes Home rates and inflation. It does not give a project-specific 2027 fee difference. A quoted taught master's fee or generic UKRI Home amount would be the wrong basis for an exact funding gap. Ask for the applicable entry-cohort fee schedule and written annual difference over the funded period.

Full-year London budget

Imperial's 2026 living-cost guidance gives £22,722 for a full year with private accommodation. Against the starting stipend, the arithmetic surplus is about £1,601 a year, or £133 a month, before tuition shortfall, arrival expenses, inflation and other exclusions. This narrow margin should not be treated as capacity to pay overseas fees. Nine-month student budget figures are unsuitable for a year-round doctorate; college-hall examples also do not guarantee postgraduate housing availability.

Application package and timing

Applications go by email to Magdalena Zak by 15 November 2026, with CV, at least two academic referee contacts, a personal statement of no more than 1,000 words and degree classifications/certificates where available. In-person interviews are planned for late November to early December 2026. The page does not provide an exact deadline time or remote-interview policy; an overseas applicant should clarify attendance arrangements early.

The subsequent formal admission stage remains subject to academic and English requirements.

Official BHF blood-protein PhD call 2026–27 doctoral fee policy and faculty routing Official 2026 Imperial living-cost budget Living-cost estimates methodology, September 2026

Applicant Background and Preparation

The advertised call accepts a first or upper-second UK bachelor's degree, a master's degree or an overseas equivalent in epidemiology, health data analytics, biostatistics, biomedical sciences or related fields. Required experience includes quantitative analysis and management of large datasets, alongside communication, literature-review ability and willingness to undertake training. It does not require prior mastery of both advanced proteomics and causal epidemiology.

These project-level degree alternatives must be read alongside Imperial's normal doctoral expectation of a master's degree plus an upper-second-equivalent bachelor's degree. Imperial assesses international qualifications by department and case. Applicants relying on the advertised bachelor's alternative, especially those with Chinese qualifications, should ask Registry or the programme contact how their credentials map to the doctoral entry requirements and whether an individual grade threshold applies. Eligibility remains subject to the university's assessment of the applicant's documents. Being permitted to compete internationally does not solve the overseas-fee gap.

Imperial publishes Standard and Higher English tiers. IELTS Academic thresholds are respectively 6.5 overall with 6.0 in each element, or 7.0 with 6.5. The exact project does not identify which tier will apply to the eventual registration route, so neither is presented as an unconditional project rule. Confirm the applicable tier, approved evidence and validity period with admissions. Imperial's cited English-language policy does not accept IELTS single-score retakes; applicants should confirm the current rule with admissions.

Suggested preparation is a short, reproducible analysis that distinguishes an assay-quality problem from a biological association. A candidate might show careful preprocessing, batch checks, a clearly specified model, an independent validation strategy and concise interpretation of limitations. Skills in R or Python, regression, survival analysis, multiple-testing control and data provenance are sensible preparation inferred from the work, not newly invented admission conditions.

The strongest starting profiles combine quantitative competence with biological reasoning. A mainly wet-lab applicant with little large-dataset experience must address a stated required skill; a machine-learning applicant who treats proteins as generic features needs preparation in assay mechanisms, epidemiology and causal assumptions. Neither background is ruled out automatically. The personal statement should explain one evidence-backed research interest and the applicant's own contribution to prior work, while referee contacts and certified qualifications support the formal assessment.

Official BHF blood-protein PhD call NHLI doctoral application route Imperial doctoral admissions expectations Current doctoral international qualifications index Imperial English requirements

Next Actions and Questions to Verify

The supervisory combination and recent joint papers provide a coherent scientific rationale, especially the challenge of preventing assay discordance from becoming a misleading biomarker or target claim. For applicants paying overseas fees, however, the explicit funding gap is a decisive practical condition. Scientific value remains strong even when financial feasibility cannot yet be established.

Before applying, request the entry-cohort overseas/Home fee difference and acceptable evidence of supplemental funding. Ask whether any project-linked supplementary award exists and whether it can be held with the BHF studentship. Obtain a Registry interpretation of Chinese qualifications and the call's bachelor/master alternatives. Clarify the applicable English tier and whether an applicant abroad can interview remotely or needs to fund travel.

At interview, ask which cohorts and assay datasets are already approved for the student, their access status, and whether a start could be delayed by data-governance or platform changes. Clarify the balance of sample preparation, MS acquisition and secondary analysis, and who provides practical training. Ask how joint supervision will manage cases where an analytically reliable marker lacks causal support, or a genetic instrument may alter affinity binding. Establish realistic first-year milestones and fallback datasets rather than rely on future large releases.

Before acceptance, check the stipend, Home-fee award and overseas supplement together for all three years. Ask about inflation, any unfunded writing period and consumable overspend. Build a full-year London budget using actual housing, deposits and commute, with separate visa/health and arrival expenses. The research allowances should remain outside personal-income calculations.

Missing public evidence includes the exact 2027 fee gap, a named overseas supplement, individual Chinese academic equivalence, current project data access and division of daily supervision. These restrictions warrant verification rather than a rejection based only on topic or institutional prestige. The practical next action is an enquiry to the advertised administrator and supervisors that focuses on fee coverage, qualification interpretation and the data already available for a 2027 start.

Official BHF blood-protein PhD call Imperial doctoral admissions expectations Current doctoral international qualifications index 2026–27 doctoral fee policy and faculty routing Official 2026 Imperial living-cost budget UK Biobank current data-access status

Evidence and Sources

The recruitment, fee, ranking and data-access conditions cited here are time-sensitive and do not establish current recruitment or access status. The Meena analysis is limited to its main methods, selected results and stated limitations; the Singh discussion uses its figure methods and author-contribution information; and the plaque study is described through its main methods, selected results and limitations. The 2026 consensus contributes abstract-level context only; detailed recommendations, supplementary materials and raw data are outside this report's evidence scope.

The cited sources support interpretation of the project and its context; they do not confirm an individual applicant's eligibility, current vacancy status, data access or final funding arrangement.

• S01: Official BHF blood-protein PhD call — official_project.

• S02: Manuel Mayr Imperial staff profile — supervisor_profile.

• S03: Ioanna Tzoulaki Imperial staff profile — official_university.

• S04: Mayr cardiovascular proteomics group research and publications — lab.

• S05: Consensus statement on MS-based cardiac-tissue proteomics — publication.

• S06: Blood pressure, plasma proteins and cardiovascular diseases — publication.

• S07: Precision medicine requires precision proteomics — publication.

• S08: QS World University Rankings 2027 primary summary — ranking.

• S09: National Heart and Lung Institute research — department.

• S10: Imperial School of Public Health — department.

• S11: NHLI doctoral application route — programme.

• S12: Imperial doctoral admissions expectations — programme.

• S13: Current doctoral international qualifications index — programme.

• S14: Imperial English requirements — programme.

• S15: 2026–27 doctoral fee policy and faculty routing — fees.

• S16: Official 2026 Imperial living-cost budget — cost_of_living.

• S17: Living-cost estimates methodology, September 2026 — cost_of_living.

• S18: UK Life Sciences Sector Plan, updated July 2026 — government.

• S19: UK Life Sciences Jobs Plan — career_market.

• S20: White City MS infrastructure and training — lab.

• S21: Current doctoral professional development support — programme.

• S22: UK Biobank biomarker and proteomic data coverage — academic_database.

• S23: UK Biobank current data-access status — academic_database.

• S24: Original plaque proteomics and outcome validation — original empirical publication; main methods, selected results and discussion/limitations actually read.